IgA Nephropathie - Prof. Dr. Jürgen Floege (Aachen)

Herr Prof. Dr. Jürgen Floege (Aachen), Work Group Co-Chair der KDIGO-Leitlinie Glomerulonephritis 2021 und Past Präsident der Deutschen Gesellschaft für Nephrologie, disktuiert etablierte und innovative Therapieoptionen für die IgA-Nephropathie.
Das Gespräch wurde am 13.02.2024 geführt. Moderatoren: Prof. Dr. Andreas Kronbichler (Innsbruck), Dr. Philipp Gauckler (Innsbruck) und Prof. Dr. Gunnar Heine (Frankfurt am Main).
Weitere Literatur:
Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial.
Fellström BC et al.; NEFIGAN Trial Investigators.
Lancet 2017
doi: 10.1016/S0140-6736(17)30550-0
Effectiveness of Mycophenolate Mofetil Among Patients With Progressive IgA Nephropathy: A Randomized Clinical Trial.
Hou FF et al.; MAIN Trial Investigators
JAMA Netw Open 2023
doi: 10.1001/jamanetworkopen.2022.54054
A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy.
Mathur M et al.; ENVISION Trial Investigators Group
N Engl J Med 2024
doi: 10.1056/NEJMoa2305635
Antimalarials in IgA Nephropathy: Did Our Supportive Therapy Armamentarium Just Increase?
Floege J
Am J Kidney Dis 2019
doi: 10.1053/j.ajkd.2019.02.022
Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Randomized Controlled Trial.
Liu LJ et al.
Am J Kidney Dis 2019
doi: 10.1053/j.ajkd.2019.01.026
Supramaximal dose of candesartan in proteinuric renal disease.
Burgess E et al.; SMART (Supra Maximal Atacand Renal Trial) Investigators.
J Am Soc Nephrol 2009
doi: 10.1681/ASN.2008040416
Targeted-release budesonide modifies key pathogenic biomarkers in immunoglobulin A nephropathy: insights from the NEFIGAN trial.
Wimbury D et al.
Kidney Int 2024
doi: 10.1016/j.kint.2023.11.003
Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial.
Pozzi C et al.
J Am Soc Nephrol 2004
doi: 10.1097/01.asn.0000103869.08096.4f
Treatment of early immunoglobulin A nephropathy by angiotensin-converting enzyme inhibitor.
Li PK et al.
Am J Med 2013
doi: 10.1016/j.amjmed.2012.06.028
Long-Term Outcomes in IgA Nephropathy.
Pitcher D et al.
Clin J Am Soc Nephrol 2023
doi: 10.2215/CJN.0000000000000135
Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy.
Barratt J et al.; NefIgArd Trial Investigators
Kidney Int 2023
doi: 10.1016/j.kint.2022.09.017
Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.
Lv J et al.; TESTING Study Group
JAMA 2022
doi: 10.1001/jama.2022.5368
A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy.
Wheeler DC et al.; DAPA-CKD Trial Committees and Investigators.
Kidney Int 2021
doi: 10.1016/j.kint.2021.03.033
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group
Kidney Int 2021
doi: 10.1016/j.kint.2021.05.021
SGLT-2 inhibition in IgA nephropathy: the new standard of care?
Barratt J, Floege J.
Kidney Int 2021
doi: 10.1016/j.kint.2021.04.002
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial.
Lafayette R et al.; NefIgArd trial investigators
Lancet 2023
doi: 10.1016/S0140-6736(23)01554-4
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.
Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium
Lancet 2022
doi: 10.1016/S0140-6736(22)02074-8

[@wilhelmbaumgartel853]

Interessantes Video 💪💪💪

[@MarkusAtHome]

Herzlichsten Dank!

[@musicloverdumdidum]

Endlich 👍

[@MarkusAtHome]

Endlich?

[@FlorianMüller-o3n]

sehr schönes Video! tolle Diskussion. weiter so!

[@MarkusAtHome]

Herzlichen Dank!

[@franciscomoreno1916]

Sehr gut

[@MarkusAtHome]

Danke!